Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

nths to December 31, 2007 decreased by 65% to $66.6 million (2006: $188.8 million). Excluding upfront payments and milestones in respect of in-licensed technology of $75.0 million in 2007 (2006: $nil) (see section 4 - R&D below for details), cash inflow from operating activities for the year to December 31, 2007 decreased by 25% to $141.6 million (2006: $188.8 million). This decrease was primarily as a result of increased receivables generated by higher sales in December 2007 over December 2006.

2. Product sales

For the year to December 31, 2007 product sales increased by 41% to $2,170.2 million (2006: $1,535.8 million) and represented 89% of total revenues (2006: 86%).

Product Highlights

Sales Sales US Rx US Average

$M Growth (2) Growth (1)(2) Annual Market

Product Share(1)

Specialty

Pharmaceuticals

ADDERALL XR 1,030.9 +19% +3% 25.5%

VYVANSE 76.5 n/a n/a 1.8%

DAYTRANA 64.2 +156% +166% 2.1%

PENTASA 176.4 +28% +3% 17.2%

LIALDA 50.5 n/a n/a 3.9%

FOSRENOL 102.2 +128% +5% 8.6%

DYNEPO 14.2 n/a n/a n/a

CARBATROL 72.3 +6% -5% 41.3%

XAGRID 66.8 +25% n/a n/a

Human Genetic Therapies

REPLAGAL 143.9 +22% n/a n/a

ELAPRASE 181.8 +670% n/a n/a

(1) Product specific prescription data is provided by IMS Health ("IMS"), a leading global provider of business intelligence for the pharmaceutical and healthcare indus
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... , Sept. 15, 2014 Zymo ... viral transport solution for safe ambient temperature storage ... molecular testing. Importantly, the infectivity of agents in such ... maintaining the integrity of the viral nucleic acids ... the recent Ebola epidemic in West ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3
... 14 At the Board of Directors,meeting held ... of,$.115 per share. The dividend is payable on ... 31, 2007. About Sigma-Aldrich: Sigma-Aldrich is a ... and organic chemical products and kits,are used in ...
... Summertime equals fun for a lot of,folks. But ... typical,summer fare could also mean aggravating their sensitive ... IBS," has more on,what people with IBS can ... from,ruining their celebrations. Listen to this report ...
... 15 /PRNewswire-FirstCall/,-- Shire plc (LSE: SHP, NASDAQ: SHPGY, ... the waiting period under,Hart-Scott-Rodino Antitrust Improvements Act of ... (human TGF BETA 3) from Renovo Group plc,(LSE: ... with its terms, the,License Agreement became effective on ...
Cached Biology Technology:Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 2Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3) 3
(Date:9/16/2014)... impact that spelled doom for the dinosaurs 66 million ... to a much greater extent than their deciduous peers, ... results are published in the journal PLOS Biology ... trove of thousands of fossilized leaves of angiosperms ... able to reconstruct the ecology of a diverse plant ...
(Date:9/16/2014)... a new football season and another commercial cargo flight ... spacecraft is scheduled to blast off to the orbital ... company,s fourth contracted mission to the complex. , Included ... research investigations sponsored by the Center for the Advancement ... managing the U.S. National Laboratory on the space station, ...
(Date:9/16/2014)... Keystone XL pipeline (KXL) would likely increase oil sands ... surveyed by the non-profit organization Near Zero. The results ... Impact," and includes both supporters and opponents of the ... sands could lead to significantly higher greenhouse gas emissions, ... respond. , "This report examines three main scenarios ...
Breaking Biology News(10 mins):Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... has identified a genetic variant that substantially increases the ... populations. The study, published by Cell Press on August ... , associates a deletion on chromosome 3 with increased ... that affects 1% of the world population. Characterized by ...
... scientists have been able to measure the amount of water that ... result -- 285 billion metric tons, or 285 cubic kilometers of ... over half the volume of Lake Erie, which is the world,s ... of the water flowing through the Amazon River every year, and ...
... Swine Flu. Rabies. These are emerging infectious diseases where ... another and now infect humans. This is a phenomenon ... to determine what drives it. Gary McCracken, a ... head in Ecology and Evolutionary Biology, is one of ...
Cached Biology News:Large risk schizophrenia marker revealed 2First satellite measurement of water volume in Amazon floodplain 2First satellite measurement of water volume in Amazon floodplain 3UT professor uncovers clues into how viruses jump from hosts 2
Spastin (Sp 3G11/1)...
mCD-1 10 transcription reactions...
... Rabbits x 2 , ... bleed x1 /each , Immunizations/Boost injections ... (app. 5 ml) x1 /each , ... /each , Final Bleed ~ 100 ml blood ...
Mouse VCAM-1/CD106 MAb (Clone 112702)...
Biology Products: